{"coverImageURL": "https://www.economist.com/media-assets/image/20230218_BLP902.jpg", "coverImageWidth": 1280, "coverImageHeight": 720, "coverImageDescription": "", "title": "This week\u2019s cover", "subtitle": "How we saw the world", "hashTag": "The world this week", "authorName": "The Economist", "publishDate": "2023-03-02T13:39:15Z", "contents": [{"role": "body", "text": "THIS WEEK\u2019S worldwide cover celebrates the new drugs promising an end to the world\u2019s obesity epidemic. They could bring riches for their makers, savings for health systems and better lives for millions."}, {"role": "image", "imageURL": "https://www.economist.com/media-assets/image/20230304_DE_US.jpg", "imageWidth": 1280.0, "imageHeight": 1684.0, "imageDescription": ""}, {"role": "body", "text": "Treatments for weight loss have long ranged from the well-meaning and ineffective to the downright dodgy. This week we write about a new class of drugs, called GLP-1 receptor agonists, that actually seems to work. "}, {"role": "body", "text": "The new drugs were first devised as a treatment for diabetes. They mimic hormones that regulate the level of glucose in the blood; suppress hunger, by keeping food in the stomach and acting directly on the brain; and make fat easier to break down."}, {"role": "body", "text": "The cover is made up of images that we played with in other, rejected designs: typography, epipen and hotdog. It\u2019s simple and powerful and, in a world with more than its share of bad news, it provides a ray of hope."}, {"role": "body", "text": "Leader: New drugs could spell an end to the world\u2019s obesity epidemicBriefing: Riches for drugmakers, huge savings for health systems and better lives for millionsBusiness: Lessons from Novo Nordisk on the stampede for obesity drugs"}, {"role": "body", "text": "For subscribers only: to see how we design each week\u2019s cover, sign up to our weekly Cover Story newsletter."}]}